Lisdexamfetamine Dimesylate

Adalvo is delighted to announce that Lisdexamfetamine Oral Solution will soon be available in the U.S. through our commercial partner, Azurity Pharmaceuticals. Arynta will be the first and only patented Lisdexamfetamine oral solution approved in the U.S. market. It will also be Adalvo's first product available in the U.S. Indicated for the treatment of ADHD in children aged six and older, as well as adults, Arynta is a ready-to-use product that answers an unmet medical need. Approximately 70% of children, and 30% of adolescents, are unable, or struggle, to swallow tablets or capsules. As a liquid, Arynta avoids this issue and offers precise dosing. As a prodrug of amphetamine, Arynta delivers reliable symptom control for up to 13 hours in children and up to 14 hours in adults. Its safety and tolerability profile is similar to that of other stimulant medication. Developed under the USA’s 505(b)(2) category, Arynta will be available in four presentations for patient convenience and more accurate dosing. Anil Okay, Adalvo's CEO comments, "We're proud to partner with Azurity to launch Arynta in the U.S. They have extensive experience bringing products to market in this therapeutic area and share our commitment to serving overlooked patients. It's also an important milestone for Adalvo — our first product in the US market, with three more to follow this year." To learn more about Adalvo’s US portfolio, contact one of the team today. About Adalvo Adalvo is Europe's fastest-growing B2B pharmaceutical company, providing 170+ partners with end-to-end capabilities spanning product conception to commercialization across 140+ countries. Headquartered in Malta with operations in 20+ countries, Adalvo's high-value portfolio includes over 30 differentiated technologies and a pipeline of ~60 projects due for market entry before 2030. About Azurity Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to addressing the critical and often invisible crisis facing overlooked patients by offering innovative solutions to meet their specific, unmet needs, which often are ignored by the broader biopharmaceutical industry and not typically addressed by generic manufacturers. By reformulating, adapting, and developing new therapies that meet specialized patient needs, we are delivering treatment alternatives that solve issues impacting patients’ day-to-day lives. Azurity has a broad portfolio of more than 50 medicines across 10 therapeutic areas fueling its mission, powered by a next generation AI-driven sales and marketing tool called Azurity Commercial Excellence (ACE) to optimize customer engagement and improve product delivery to overlooked patients. For more information, visit www.azurity.com.